ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Lincoln Pharmaceuticals has dispatched physical letters to shareholders with unregistered email IDs to provide access to the Annual Report for FY 2025-26 and facilitate KYC updates.
Lincoln Pharmaceuticals submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory adherence with no major non-compliances.
Lincoln Pharmaceuticals Ltd confirmed it does not meet the SEBI criteria for 'Large Corporate' classification for FY 2025-26. The company reported zero outstanding long-term borrowings and zero mandatory debt sourcing requirements for the period, maintaining its status as a mid-sized corporate entity for regulatory purposes.
Lincoln Pharmaceuticals Ltd submitted its quarterly confirmation certificate for the period ended March 31, 2026, as required under SEBI regulations. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed that security certificates received for dematerialisation were processed and listed on the stock exchanges within prescribed timelines.